Across TCGA pan-cancer cohorts, EVL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EVL data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher EVL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EVL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, LGG, and UCEC are the cancer types where EVL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LGG	DFS	Median	All	0.185	0.832	<.001	6	view →
UCEC	OS	Median	All	1.000	0.662	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: EVL tumor-vs-normal RNA expression · all EVL data types